Kick-off of the NOAR network, the COST project dedicated to the development of alpha therapy
On 22 October 2020 in Brussels, the COST (COoperation in Science and Technology) project dedicated to the development of alpha
SIRIC ILIAD shares the progress of its research with its partners
The SIRIC ILIAD Partners and Patient Representatives Committee met on 11 September to present its mid-term review. On 11 September
Clinical trial: FICTIoN Cohort
FICTIoN Cohort: Radiomic analyses of 18FDG PET and correlation with histology Type of study: Single-centre study Pathology: Triple-negative breast cancer,
Telix – SIRIC ILIAD Collaboration: TLX102 multiple myeloma treatment receives FDA orphan drug designation
The TLX102 treatment, resulting from the collaboration between Telix Pharmaceuticals (Australia), Osaka University (Japan) and the SIRIC ILIAD nuclear medicine
